Mind Pharmaceuticals
Clinical-stage company focused on developing short-acting, rapid-onset therapeutics for CNS disorders, initially targeting treatment-resistant depression (TRD) and headache disorders. Development activities include intravenous and oral formulations of classical serotonergic psychoactive compounds, phase 1/2 clinical studies, and formulation research aimed at enabling scalable outpatient treatment paradigms.
Industries
N/A
Nr. of Employees
small (1-50)
Mind Pharmaceuticals
Connecticut Financial Center, 157 Church St, 19th Floor, New Haven, CT 06510, USA
Products
Intravenous N,N-dimethyltryptamine formulation for treatment-resistant depression
Intravenous formulation of N,N-dimethyltryptamine developed for treatment-resistant depression; completed an exploratory Phase 1/2 study (n=10) and conducting a larger trial (n≈60). Clinical data reported short duration of acute effects (~30 minutes), rapid onset of antidepressant effect (observed the day after dosing), and reductions in HAMD-17 scores.
Oral psilocybin formulation for migraine and cluster headaches
Oral formulation development intended for treatment of migraine and cluster headache disorders; early exploratory clinical data suggest single-dose reductions in weekly migraine days versus placebo in a crossover study.
Intravenous N,N-dimethyltryptamine formulation for treatment-resistant depression
Intravenous formulation of N,N-dimethyltryptamine developed for treatment-resistant depression; completed an exploratory Phase 1/2 study (n=10) and conducting a larger trial (n≈60). Clinical data reported short duration of acute effects (~30 minutes), rapid onset of antidepressant effect (observed the day after dosing), and reductions in HAMD-17 scores.
Oral psilocybin formulation for migraine and cluster headaches
Oral formulation development intended for treatment of migraine and cluster headache disorders; early exploratory clinical data suggest single-dose reductions in weekly migraine days versus placebo in a crossover study.
Expertise Areas
- Clinical trial management (early-stage CNS trials)
- Psychedelic therapeutics and serotonergic compound development
- Formulation development (intravenous and oral)
- Regulatory affairs, CMC and quality for IND/CTA filings
Key Technologies
- Intravenous drug formulation
- Oral drug formulation
- Double-blind placebo-controlled crossover trial design
- Dose-ranging safety and tolerability protocols
News & Updates
Peer-reviewed publication reporting an exploratory study of dose-related safety, tolerability, and efficacy of DMT in healthy volunteers and patients with major depressive disorder (Neuropsychopharmacology, 2022).
Peer-reviewed exploratory controlled study reporting reduction in weekly migraine days after a single administration of oral psilocybin (Neuotherapeutics, 2021).
Completed an exploratory trial (n=10) of an intravenous serotonergic compound in TRD showing significant reduction in HAMD-17 scores the day after dosing (mean difference −4.5 at 0.3 mg/kg) with no dropouts and transient physiological effects.
Peer-reviewed publication reporting an exploratory study of dose-related safety, tolerability, and efficacy of DMT in healthy volunteers and patients with major depressive disorder (Neuropsychopharmacology, 2022).
Peer-reviewed exploratory controlled study reporting reduction in weekly migraine days after a single administration of oral psilocybin (Neuotherapeutics, 2021).
Completed an exploratory trial (n=10) of an intravenous serotonergic compound in TRD showing significant reduction in HAMD-17 scores the day after dosing (mean difference −4.5 at 0.3 mg/kg) with no dropouts and transient physiological effects.